XDNA

Kelly CRISPR & Gene Editing Technology ETF [XDNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XDNA Stock Summary

In the News

XDNA Financial details

Company Rating
-
Market Cap
2.58M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.01
Dividend %
0.13%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.87-11.83
52W High
-
52W Low
-
RSI
-
Rel Volume
0.84
Avg Volume
5.04K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

XDNA Financial Performance

XDNA Dividend History

XDNA Frequently Asked Questions

What is Kelly CRISPR & Gene Editing Technology ETF stock symbol ?

Kelly CRISPR & Gene Editing Technology ETF is a stock and trading under the symbol XDNA

What is Kelly CRISPR & Gene Editing Technology ETF stock quote today ?

Kelly CRISPR & Gene Editing Technology ETF stock price is $- today.

Is Kelly CRISPR & Gene Editing Technology ETF stock public?

Yes, Kelly CRISPR & Gene Editing Technology ETF is a publicly traded company.

Something similar

Top by Market Cap
1YD.DE
AMZN
M&M.NS
NVDA
3V64.DE
Interesting
ELOX
VERBW
UNG.L
8242.HK
000910.SZ
Check Those
LND
CKT.L
1788.HK
600345.SS
1731.TW
Similar Market Cap
SALL.L
VRL.DE
DATS
ALDS
SGBX

Company Profile

  • Volume Average 5.04K
  • Market Capitalization 2.58M
  • IPO Date 2022-01-13

The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.